Search results
Results from the WOW.Com Content Network
For primary liver cancer (HCC), two large trials comparing SIRT with standard of care chemotherapy, Sorafenib, have been completed, namely the SARAH [15] and SIRveNIB [16] trials. Results of these studies, published in 2017 and 2018, reported no superiority of SIRT over chemotherapy in terms of overall survival (SARAH, [17] SIRveNIB, [18 ...
Primary liver cancer, also known as hepatocellular carcinoma (HCC), is the most frequent type of liver cancer, accounting for approximately 90% of the primary malignant liver tumours in adults. Liver cancer is the sixth most prevalent malignancy and the third greatest cause of cancer-related deaths worldwide. [5] Every year, around 600,000 ...
The latter is an FDA-approved treatment for primary liver cancer which has been shown in clinical trials to increase the survival rate of low-risk patients. SIR-Spheres are FDA-approved for the treatment of metastatic colorectal cancer , but outside the US, SIR-Spheres are approved for the treatment of any nonresectable liver cancer including ...
Most tumors within the liver are supplied by the proper hepatic artery, so arterial embolization preferentially interrupts the tumor's blood supply and stalls growth until neovascularization. Secondly, focused administration of chemotherapy allows for delivery of a higher dose to the tissue while simultaneously reducing systemic exposure, which ...
Over a 45-years span — between 1975 and 2020 — improvements in cancer screenings and prevention strategies have reduced deaths from five common cancers more than any advances in treatments ...
In the United States there has been an increase in the 5-year relative survival rate between people diagnosed with cancer in 1975-1977 (48.9%) and people diagnosed with cancer in 2007-2013 (69.2%); these figures coincide with a 20% decrease in cancer mortality from 1950 to 2014. [8]
SIR-Spheres microspheres are used to treat patients with unresectable liver cancer. These are mostly patients with hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), or metastatic neuroendocrine tumours (mNET). [1] Therapy goals are local disease control, downstaging to resection, bridging to transplantation, and extended ...
In a series of 322 patients undergoing bland embolization for HCC with a median follow-up of 20 months, 1-, 2-, and 3- year overall survival rates were 66%, 46% and 33% respectively. When patients with extra-hepatic disease or portal vein involvement were excluded, overall 1-, 2- and 3-year survival rates rose to 84%, 66% and 51%, and median ...